Compare RLMD & CHMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLMD | CHMG |
|---|---|---|
| Founded | 2004 | 1833 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.8M | 415.9M |
| IPO Year | 2012 | 1995 |
| Metric | RLMD | CHMG |
|---|---|---|
| Price | $3.06 | $83.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $10.75 | ★ $92.35 |
| AVG Volume (30 Days) | ★ 1.7M | 48.9K |
| Earning Date | 11-12-2026 | 10-22-2026 |
| Dividend Yield | N/A | ★ 1.69% |
| EPS Growth | ★ 45.28 | N/A |
| EPS | N/A | ★ 6.36 |
| Revenue | ★ $13,070.00 | N/A |
| Revenue This Year | N/A | $31.95 |
| Revenue Next Year | N/A | $7.35 |
| P/E Ratio | ★ N/A | $13.37 |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $3.07 | $50.31 |
| 52 Week High | $8.00 | $89.34 |
| Indicator | RLMD | CHMG |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 47.90 |
| Support Level | N/A | $83.83 |
| Resistance Level | $3.55 | $84.69 |
| Average True Range (ATR) | 0.43 | 2.01 |
| MACD | -0.04 | -0.27 |
| Stochastic Oscillator | 4.05 | 13.43 |
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.